文献速递泌尿男性生殖肿瘤

并发肿瘤事件对胚系BRCA2突变携带者前列腺癌结局的影响

Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
PubMed 文献 · Eur J Cancer · 2023-03-05

本研究对比73例胚系BRCA2突变携带者与127例非携带者的肿瘤特征及临床结局,发现携带者中BRCA2-RB1共缺失和MYC扩增富集,且这些事件的存在或缺失改变携带者的结局。

要点

  • gBRCA2携带者中BRCA2-RB1共缺失(41% vs 12%)和MYC扩增(53.4% vs 18.8%)较散发性肿瘤富集。
  • gBRCA2携带者中位CSS为9.1年,非携带者为17.6年(HR 2.12;p=0.002)。
  • 无BRCA2-RB1缺失或MYC扩增时,gBRCA2携带者中位CSS分别升至11.3年和13.4年。

核心结论

  • gBRCA2相关前列腺肿瘤富集侵袭性基因组特征,如BRCA2-RB1共缺失和MYC扩增。
  • 这些事件的存在或缺失改变gBRCA2携带者的结局。

研究设计与样本

  • 研究纳入73例gBRCA2携带者和127例非携带者,对比其肿瘤特征与临床结局。
  • 采用荧光原位杂交和二代测序检测BRCA2、RB1、MYC和PTEN的拷贝数变异。
  • 评估导管内和筛状亚型的存在。
  • 采用Cox回归模型评估这些事件对病因特异性生存、无转移生存和至去势抵抗疾病时间的独立影响。

主要发现

  • gBRCA2携带者中BRCA2-RB1共缺失为41%,非携带者为12%(p < 0.001)。
  • gBRCA2携带者中MYC扩增为53.4%,非携带者为18.8%(p < 0.001)。
  • gBRCA2携带者中位CSS为9.1年,非携带者为17.6年(HR 2.12;p = 0.002)。
  • 无BRCA2-RB1缺失时gBRCA2携带者中位CSS为11.3年,无MYC扩增时为13.4年。
  • 非携带者中检测到BRCA2-RB1缺失或MYC扩增时,中位CSS分别降至8年和2.6年。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several studies have reported the association of germline BRCA2 (gBRCA2) mutations with poor clinical outcomes in prostate cancer (PCa), but the impact of concurrent somatic events on gBRCA2 carriers survival and disease progression is unknown. PATIENTS AND METHODS: To ascertain the role of frequent somatic genomic alterations and histology subtypes in the outcomes of gBRCA2 mutation carriers and non-carriers, we correlated the tumour characteristics and clinical outcomes of 73 gBRCA2 and 127 non-carriers. Fluorescent in-situ hybridisation and next-generation sequencing were used to detect copy number variations in BRCA2, RB1, MYC and PTEN. Presence of intraductal and cribriform subtypes was also assessed. The independent impact of these events on cause-specific survival (CSS), metastasis-free survival and time to castration-resistant disease was assessed using cox-regression models. RESULTS: Somatic BRCA2-RB1 co-deletion (41% versus 12%, p < 0.001) and MYC amplification (53.4% versus 18.8%, p < 0.001) were enriched in gBRCA2 compared to sporadic tumours. Median CSS from diagnosis of PCa was 9.1 versus 17.6 years in gBRCA2 carriers and non-carriers, respectively (HR 2.12; p = 0.002), Median CSS in gBRCA2 carriers increased to 11.3 and 13.4 years in the absence of BRCA2-RB1 deletion or MYC amplification, respectively. Median CSS of non-carriers decreased to 8 and 2.6 years if BRCA2-RB1 deletion or MYC amplification were detected. CONCLUSIONS: gBRCA2-related prostate tumours are enriched for aggressive genomic features, such as BRCA2-RB1 co-deletion and MYC amplification. The presence or absence of these events modify the outcomes of gBRCA2 carriers.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lozano R, Castro E, Lopez-Campos F, et al. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. Eur J Cancer. 2023. PMID: 36972661. doi:10.1016/j.ejca.2023.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。